000472

84 / 86

40. Comparison of rifaximin and lactitil in the treatment of acute hepatic
encephalopathy/A. Mas [et al.]//J. Hepatol. – 2003. – Vol. 38. – P. 51–58.
41.Ishak, KG. Chronic hepatitis. Morphology and nomenclature/KG. Is-
hak//Modern Pathol. – 1994. – V. 7. – P. 690–713.
42. de Franchis, R. Updating consensus in portal hypertension: report
of the Baveno III consensus workshop on definitions, methodology and
therapeutic strategies in portal hypertension/R. de Franchis//J. Hepatology. –
2000. – V. 33. – P. 846–852.
43. Malchesky, P. S. Apheresis technologies: an international perspective
/P. S. Malchesky, R. Bambauer, T. Horiuchi//Artificial organs. – 1995. –Vol. 19. –
P. 56–67.
44. Natural history of portal hypertensive gastropathy in patients with
liver cirrhosis. New Italian Endoscopic Club for the study and treatment of
esophageal varices (NIEC)/M. Primignani [et al.]//Gastroenterology. – 2000. –
Vol. 119. – P.181–187.
45. Prevalence and natural history of subclinical hepatic encepha-
lopathy in cirrhosis/A. Das [et al.]//J. Gastroenterol. Hepatol. – 2001. – Vol. 16. –
P. 531–535.
46. Role of zinc in subclinical hepatic encephalopathy: comparison with
somatosensory-evoked potentials/S. S. Yang [et al.]//J. of gastroenterol. and.
hepatol. – 2004. – Vol. 19. – P. 375–379.
47.Stanley,A. J. Portalhypertensionandvaricealhaemorrhage/A. J. Stanley,
P. C. Hayes//Lancet. – 1997. – V. 350. – P. 1235–1239.
48. The morphology of cirrhosis: Definition, nomenclature and classification
/P. P. Anthony [et al.]//Bull. WHO. – 1977. – V. 55. – P. 521–524.
49. The management of portal hypertension: Rational basis, available
treatment and future options/J. Bosch [et al.]//J. Hepatol. – 2008. – Vol. 48. –
P. 68–93.
50. Visual eventrelated P300 in early portosystemic encephalopathy/C. Kug-
ler [et al.]//Gastroenterology. – 1992. – N 1. – P. 302–310.